These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 26360610)

  • 1. POL5551, a novel and potent CXCR4 antagonist, enhances sensitivity to chemotherapy in pediatric ALL.
    Sison EA; Magoon D; Li L; Annesley CE; Romagnoli B; Douglas GJ; Tuffin G; Zimmermann J; Brown P
    Oncotarget; 2015 Oct; 6(31):30902-18. PubMed ID: 26360610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CXCR4 Protein Epitope Mimetic Antagonist POL5551 Disrupts Metastasis and Enhances Chemotherapy Effect in Triple-Negative Breast Cancer.
    Xiang J; Hurchla MA; Fontana F; Su X; Amend SR; Esser AK; Douglas GJ; Mudalagiriyappa C; Luker KE; Pluard T; Ademuyiwa FO; Romagnoli B; Tuffin G; Chevalier E; Luker GD; Bauer M; Zimmermann J; Aft RL; Dembowsky K; Weilbaecher KN
    Mol Cancer Ther; 2015 Nov; 14(11):2473-85. PubMed ID: 26269605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dynamic chemotherapy-induced upregulation of CXCR4 expression: a mechanism of therapeutic resistance in pediatric AML.
    Sison EA; McIntyre E; Magoon D; Brown P
    Mol Cancer Res; 2013 Sep; 11(9):1004-16. PubMed ID: 23754844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plerixafor as a chemosensitizing agent in pediatric acute lymphoblastic leukemia: efficacy and potential mechanisms of resistance to CXCR4 inhibition.
    Sison EA; Magoon D; Li L; Annesley CE; Rau RE; Small D; Brown P
    Oncotarget; 2014 Oct; 5(19):8947-58. PubMed ID: 25333254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML.
    Zeng Z; Shi YX; Samudio IJ; Wang RY; Ling X; Frolova O; Levis M; Rubin JB; Negrin RR; Estey EH; Konoplev S; Andreeff M; Konopleva M
    Blood; 2009 Jun; 113(24):6215-24. PubMed ID: 18955566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The novel CXCR4 antagonist POL5551 mobilizes hematopoietic stem and progenitor cells with greater efficiency than Plerixafor.
    Karpova D; Dauber K; Spohn G; Chudziak D; Wiercinska E; Schulz M; Pettit AR; Levesque JP; Romagnoli B; Patel K; Chevalier E; Dembowsky K; Bonig H
    Leukemia; 2013 Dec; 27(12):2322-31. PubMed ID: 24072044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of CXCR4 with the novel RCP168 peptide overcomes stroma-mediated chemoresistance in chronic and acute leukemias.
    Zeng Z; Samudio IJ; Munsell M; An J; Huang Z; Estey E; Andreeff M; Konopleva M
    Mol Cancer Ther; 2006 Dec; 5(12):3113-21. PubMed ID: 17172414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CXCR4 antagonists mobilize childhood acute lymphoblastic leukemia cells into the peripheral blood and inhibit engraftment.
    Juarez J; Dela Pena A; Baraz R; Hewson J; Khoo M; Cisterne A; Fricker S; Fujii N; Bradstock KF; Bendall LJ
    Leukemia; 2007 Jun; 21(6):1249-57. PubMed ID: 17410186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MLL-rearranged acute lymphoblastic leukaemia stem cell interactions with bone marrow stroma promote survival and therapeutic resistance that can be overcome with CXCR4 antagonism.
    Sison EA; Rau RE; McIntyre E; Li L; Small D; Brown P
    Br J Haematol; 2013 Mar; 160(6):785-97. PubMed ID: 23294096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The CXCR4 antagonist POL5551 is equally effective as sirolimus in reducing neointima formation without impairing re-endothelialisation.
    Hamesch K; Subramanian P; Li X; Dembowsky K; Chevalier E; Weber C; Schober A
    Thromb Haemost; 2012 Feb; 107(2):356-68. PubMed ID: 22234341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemosensitivity is differentially regulated by the SDF-1/CXCR4 and SDF-1/CXCR7 axes in acute lymphoblastic leukemia with MLL gene rearrangements.
    Ando N; Furuichi Y; Kasai S; Tamai M; Harama D; Kagami K; Abe M; Goi K; Inukai T; Sugita K
    Leuk Res; 2018 Dec; 75():36-44. PubMed ID: 30453100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Involvement of chemokine receptor 4/stromal cell-derived factor 1 system during osteosarcoma tumor progression.
    Perissinotto E; Cavalloni G; Leone F; Fonsato V; Mitola S; Grignani G; Surrenti N; Sangiolo D; Bussolino F; Piacibello W; Aglietta M
    Clin Cancer Res; 2005 Jan; 11(2 Pt 1):490-7. PubMed ID: 15701832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of pharmacological and genetic disruption of CXCR4 chemokine receptor function in B-cell acute lymphoblastic leukaemia.
    Randhawa S; Cho BS; Ghosh D; Sivina M; Koehrer S; Müschen M; Peled A; Davis RE; Konopleva M; Burger JA
    Br J Haematol; 2016 Aug; 174(3):425-36. PubMed ID: 27071778
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antileukemia activity of the novel peptidic CXCR4 antagonist LY2510924 as monotherapy and in combination with chemotherapy.
    Cho BS; Zeng Z; Mu H; Wang Z; Konoplev S; McQueen T; Protopopova M; Cortes J; Marszalek JR; Peng SB; Ma W; Davis RE; Thornton DE; Andreeff M; Konopleva M
    Blood; 2015 Jul; 126(2):222-32. PubMed ID: 26031918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [SDF-1α/CXCR4 Mediated Drug Resistance Can be Reversed by Ibrutinib in Acute Lymphoblastic Leukemia].
    Hu YY; Tao SD; Ma JJ; Zhou LT; Chen Y; Yu L
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Jun; 25(3):754-760. PubMed ID: 28641630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Expression of SDF-1alpha and its receptor CXCR4 in acute leukemias and their relationship with extramedullary infiltration].
    Liu ZR; Sun H; Zou P
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Feb; 14(1):1-5. PubMed ID: 16584580
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multifaceted C-X-C Chemokine Receptor 4 (CXCR4) Inhibition Interferes with Anti-Vascular Endothelial Growth Factor Therapy-Induced Glioma Dissemination.
    Gagner JP; Sarfraz Y; Ortenzi V; Alotaibi FM; Chiriboga LA; Tayyib AT; Douglas GJ; Chevalier E; Romagnoli B; Tuffin G; Schmitt M; Lemercier G; Dembowsky K; Zagzag D
    Am J Pathol; 2017 Sep; 187(9):2080-2094. PubMed ID: 28734730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of inhibitors of the chemokine receptor CXCR4 on acute lymphoblastic leukemia cells in vitro.
    Juarez J; Bradstock KF; Gottlieb DJ; Bendall LJ
    Leukemia; 2003 Jul; 17(7):1294-300. PubMed ID: 12835717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disturbed CXCR4/CXCL12 axis in paediatric precursor B-cell acute lymphoblastic leukaemia.
    van den Berk LC; van der Veer A; Willemse ME; Theeuwes MJ; Luijendijk MW; Tong WH; van der Sluis IM; Pieters R; den Boer ML
    Br J Haematol; 2014 Jul; 166(2):240-9. PubMed ID: 24697337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stromal cell-derived factor-1/chemokine (C-X-C motif) ligand 12 stimulates human hepatoma cell growth, migration, and invasion.
    Sutton A; Friand V; Brulé-Donneger S; Chaigneau T; Ziol M; Sainte-Catherine O; Poiré A; Saffar L; Kraemer M; Vassy J; Nahon P; Salzmann JL; Gattegno L; Charnaux N
    Mol Cancer Res; 2007 Jan; 5(1):21-33. PubMed ID: 17259344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.